03-Oct-2026 17:04:16
AUROPHARMAGeneral news
AUROBINDO PHARMA : USFDA APPROVES PERAMPANEL TABLETS
• The product will be manufactured at Unit-IV of APL Healthcare, a subsidiary of Aurobindo Pharma, and is slated for launch in Q3FY27. • The approved product targets an estimated market size of US$67 million for the twelve months ending August 2026. • Aurobindo Pharma now holds 599 ANDA approvals from USFDA, comprising 574 final and 25 tentative approvals. • Impact: New USFDA approval for Perampanel Tablets.
Aurobindo Pharma Limited
Open attachment